These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20117828)

  • 1. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
    Nimeiri HS; Oza AM; Morgan RJ; Huo D; Elit L; Knost JA; Wade JL; Agamah E; Vokes EE; Fleming GF
    Gynecol Oncol; 2010 Apr; 117(1):37-40. PubMed ID: 20117828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
    Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
    Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
    Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ; Moore MJ
    Invest New Drugs; 2011 Oct; 29(5):1045-9. PubMed ID: 20191303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
    Mackay HJ; Buckanovich RJ; Hirte H; Correa R; Hoskins P; Biagi J; Martin LP; Fleming GF; Morgan R; Wang L; Polintan R; Oza AM
    Gynecol Oncol; 2012 Apr; 125(1):136-40. PubMed ID: 22138373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
    Williamson SK; Moon J; Huang CH; Guaglianone PP; LeBlanc M; Wolf GT; Urba SG
    J Clin Oncol; 2010 Jul; 28(20):3330-5. PubMed ID: 20498388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
    Matei D; Sill MW; Lankes HA; DeGeest K; Bristow RE; Mutch D; Yamada SD; Cohn D; Calvert V; Farley J; Petricoin EF; Birrer MJ
    J Clin Oncol; 2011 Jan; 29(1):69-75. PubMed ID: 21098323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
    Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
    BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
    Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
    Bodnar L; Górnas M; Szczylik C
    Gynecol Oncol; 2011 Oct; 123(1):33-6. PubMed ID: 21723597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
    N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
    Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
    J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
    Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
    Pacey S; Ratain MJ; Flaherty KT; Kaye SB; Cupit L; Rowinsky EK; Xia C; O'Dwyer PJ; Judson IR
    Invest New Drugs; 2011 Jun; 29(3):481-8. PubMed ID: 20016927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
    Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
    BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.